Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 3, 2006, Pages 319-333

  Gosse, Philippe ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Diabetes; Drug combination; End organ damage; Hypertension; Left venticular hypertrophy; Perindopril indapamide

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LOSARTAN; PERINDOPRIL; PLACEBO; VALSARTAN;

ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EUROPE; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOKALEMIA; LABORATORY TEST; LOW DRUG DOSE; MEDICAL LITERATURE; MEDICAL SOCIETY; MICROANGIOPATHY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRACTICE GUIDELINE; PREDICTION; PULSE PRESSURE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; TARGET ORGAN; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIURETICS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; INDAPAMIDE; PERINDOPRIL; RANDOMIZED CONTROLLED TRIALS; RATS;

EID: 33744454392     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.3.319     Document Type: Article

References (65)

1. Kearny PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223 (2005).
2. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
3. 3 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertension 21, 1011-1053 (2003).
4. WHO-ISH Guidelines Subcommittee. 1999 WHO-ISH Guidelines for the management of mild hypertension. J. Hypertension 17, 151-183 (1999).
5. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation and, Treatment of High Blood Pressure (JNC-VI). Arch. Intern. Med. 157, 2413-2446 (1997).
6. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002).
7. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351, 1755-1762 (1998).
8. Dahlöf B, Hansson L, Lindholm LH et al. Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. Clin. Exp. Hypertension 15, 925-939 (1993).
9. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type-2 diabetes (IDNT). N. Engl. J. Med. 345, 851-860 (2001).
10. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type-2 diabetes and nephropathy (RENAAL). N. Engl. J. Med. 345, 861-869 (2001).
11. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type-2 diabetes. UKPDS 38. Br. Med. J. 317, 703-713 (1998).
12. Weber MA, Julius ST, Kjeldsen SE et al. Blood pressure dependent and independent effects on antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363, 2047-2049 (2004).
13. Hurst M, Jarvis B. Perindopril: an updated review of its use in hypertension. Drugs 61(6), 867-896 (2001).
14. Chaffman M, Heel RC, Brogden RN et al. Indapamide: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 28, 189-235 (1984).
15. McClellan KJ, Markham A. Perindopril 2 mg/ indapamide 0.625 mg: fixed low-dose combination. Drugs 58, 297-302 (1999).
16. Richard V, Joannides R, Henry J-P et al. Fixed dose combination of perindopril with indapamide in spontaneously hypertensive rats: hemodynamic, biological and structural effects. J. Hypertension 14, 1447-1454 (1996).
17. Hayakawa H, Cofee K, Raji L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 96, 2407-2413 (1997).
18. Levy BI, Duriez M, Samuel JL. Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am. J. Hypertension 14, 7-13 (2001).
19. Rakusan K, Cicutti N, Maurin A et al. The effect of treatment with ACE Inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats. Microcirc. Res. 59,243-254 (2000).
20. Renaud IM, Chainey A, Belair MF et al. Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination. Fundam. Clin. Pbarmacol. 18, 437-447 (2004).
21. Doucet J, Richard V, Hogie M et al. Renal effects of the combined treatment with low doses of angiotensin converting enzyme inhibitor perindopril and the diuretic/vasodialtor indapamide in spontaneously hypertensive rats. Fundam. Clin. Pharmacol. 10, 186 (1996).
22. Lachaud-Petiti V, Lachau-Durand S, Duvauchelle T, Pennaforte S, Guez D. Bioequivalence study of combination of indapamide and perindopril administered as one tablet or two capsules after oral single dose. Am. J. Hypertension 8(4), 181A (1995).
23. Safar M. Determination of the optimal oral dose of indapamide (0.625, 1.25 or 2.5 mg) in combination with perindopril 4 mg, for 8 weeks in patients with mild to moderate essential hypertension. A randomised, double blind, parallel group study versus perindopril 4 mg and versus indapamide 1.25 mg. Servier Internal Report (1996).
24. Laveille C, Jochemsen R. A population pharmacokinetics analysis of an oral fixed combination perindopril 4 mg/indapamide 1.25 mg in patients with mild to moderate essential hypertension. Servier Internal Report (1996).
25. Laveille C, Lachaud-Petiti V, Guez D, Jochemsen R. Pharmacocinetique de population chez l'insuffisant rénal hypertendu: évaluation de l'assocaition perindopril/ indapamide. Arch. Mal. Coeur. Vaiss. 53, 89HS (1996).
26. Meyrier A, Dratwa M, Sennesael J, Lachaud-Pettiti V. Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure. Am. J. Hypertension 11, 1087-1092 (1998).
27. Forette B. Twelve weeks non controlled study of fixed combination of perindopril 2 mg/ indapamide 0.625 mg in elderly hypertensive patients with pharmacokinetic population approach. J. Hum. Hypertension 13, 211-213 (1999).
28. Schiavi P, Piraube C, Lachau-Durand S et al. Pharmacokinetic evaluation of the potential interaction between perindopril and indapamide at steady state after once daily administration. Am. J. Hypertension 7, 56A (1994).
29. Safar M, Zanchetti A, Sever PS et al. Perindopril and indapamide as a combination in the treatment of mild to moderate hypertension: a double-blind, randomised, placebo-controlled European multicenter study. Am. J. Hypertension 7, 42A-43A (1994).
30. Myers MG, Asmar R, Leenen FHH, Safar M. Fixed low-dose combination therapy in hypertension - a dose response study of perindopril and indapamide. J. Hypertension 18, 317-325 (2000).
31. Laurent S. Very low-dose combination of perindopril and indapamide: efficacy on blood pressure and target organ damage. J. Hypertension 21(3), 11-18 (2003).
32. Castaigne A, Chalmers J, Morgan T, Chastang C, Feldmann L, Guez D. Efficacy and safety of an oral fixed low-dose perindopril 2 mg/ indapamide 0.625 mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension. Clin. Exp. Hypertension 21(7), 1097-1110 (1999).
33. Chalmers J, Castaigne A, Morgan T, Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/ diuretic combination as first-line therapy in elderly hypertensive patients. J. Hypertension 18, 327-337 (2000).
34. Asmar RG, London GM, O'Rourke ME, Safar M Improvement in blood pressure arterial stiffness and wave reflections with a very-low-dose perindopril/ indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 38, 922-926 (2001).
35. Chanudet X, de Champvallins M. Antihypertensive efficacy and tolerability of the low-dose perindopril - indapamide combination compared with losartan in the treatment of essential hypertension. Int. J. Clin. Pract. 55, 233-239 (2001).
36. Morgan T, Anderson A. Low-dose combination therapy with perindopril and indapamide compared with irbesartan. Clin. Drug. Invest. 22, 553-560 (2002).
37. Dahlöf B, Gosse P, Guéret P et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J. Hypertension 23, 2063-2070 (2005).
38. Franklin SS, Larson MG, Khan SA et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 103, 1245-1249 (2001).
39. Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37, 1236-1241 (2001).
40. Amar J, Ruidavets JB, Peyrieux JC et al, on behalf of the investigators of the REASON trial. Comparison of a low-dose combination of perindopril/ indapamide versus atenolol in the lowering of C-reactive protein (CRP) levels along with pulse pressure (PP) reduction. Hypertension 46, 151-155 (2005).
41. Mourad JJ, Waeber B, Zannad F et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/ indapamide versus a sequential monotherapy or a stepped-care approach. J. Hypertension 22, 2379-2386 (2004).
42. Mourad JJ, Waeber B, Zannad F et al. Efficacy of a first-line low-dose ACEI/diuretic combination therapy (PRETERAX) in stage II hypertensive patients. J Hypertension 23(2), S113 (2005).
43. Fleischmann EH, Schmieder R. Are all antihypertensive drug classes equal in reducing left-ventricular hypertrophy? Curr. Cardiol. Rep. 4, 474-478 (2002).
44. Maschio, G, Marcantoni C, Bernich P. Lessons from large interventional trials on antihypertensive therapy in chronic renal disease. Nephrol. Dial. Transplant. 17(11), 47-49 (2002).
45. De Luca N, Mallion JM, O'Rourke MF et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination. The REASON echocardiography study Am. J. Hypertension 17, 660-667 (2004).
46. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Diabetes in America. National Diabetes Data Group (Ed.). NIH publishers, Washington DC, USA. US Govt Printing Office, no 95-1468, 429-448 (1995).
47. Stamler J, Dyer AR, Shekelle RB. Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. Cardiology 82, 191-222 (1993).
48. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type-2 diabetes. UKPDS 38. Br. Med. J. 317, 703-713 (1998).
49. Tuomilehto J, Rastenyte D, Birkenhager WH et al. for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium channel blockers in older patients with diabetes and systolic hypertension (Syst-Eur). N. Engl. J. Med. 340, 677-684 (1999).
50. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). Br. Med. J. 328, 634-640 (2004).
51. American Diabetes Association. Position Statement: hypertension management in adults with diabetes. Diabetes Cate 27(1), S650150S67 (2004).
52. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch. Intern. Med. 157, 1413-1418 (1997).
53. Mogensen CE, Viberti G, Halimi S et al. Effect of low-dose perindopril/ indapamide on albuminuria in diabetes (PREMIER). Hypertension 41, 1063-1071 (2003).
54. The ADVANCE Collaborative Group. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with Type-2 diabetes mellitus. J. Hypertension 19(4), S21-S28 (2001).
55. Patel A, Joshi R, Colman S, Chalmers J, Neal B, MacMahon S. Effects of low dose perindopril-indapamide combination on blood pressure in Type-2 diabetes: the ADVANCE trial run-in phase. J. Hypertension 23(2), S212. (2005) (Abstract P2. 234).
56. Camici P, Gropler RJ, Jones T et al. The impact of myocardial blood flow quantitation with PET on the understanding of cardiac disease. Eur. Heart J. 17, 25-34 (1996).
57. Mourad JJ, Hanon O, Deverre JR et al. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/ diuretic therapy: a pilot PET study. J. Renin. Angiotensin Aldosterone Syst. 4(2), 94-5 (2003).
58. Comprehensive safety summary. European Registration. Data on file.
59. Lindholm L, Ejlertsson G, Schersten B. High risk of cerebrocardiovascular morbidity in well-treated male hypertensives: a retrospective study of 40-59-year-old hypertensives in a Swedish primary care district. Acta Med. Scand. 216, 251-259 (1984).
60. Isles CG, Walker LM, Beevers GD et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J. Hypertension 4, 141-156 (1986).
61. PROGRESS Collaborative Group: Randomised trial of a perindopril based blood pressure loweing regimen amomg 6105 individuals with previous stroke or transient ischemic attack (corr. Published Lancet 358, 1556 (2001) and Lancet 359, 2120 (2002)) Lancet 358, 1033-1041 (2001).
62. Strippoli GFM, Craig M, Deeks JJ, Schena, FP, Craig JC. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systemic review. Br. Med. J. 329, 1-12 (2004).
63. Epstein BJ, Gums JG. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. Ann. Pharmacother. 39, 470-80 (2005).
64. Dahlöf B, Sever PS, Poulter NR et al, (ASCOT Investigators). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895-906 (2005).
65. ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker verus diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981-2997 (2002).